Identification of a cellular ligand for the natural cytotoxicity receptor NKp44

Blood

Volumn 122, Issue 17, 2013, Pages 2935-2942

  Baychelier, Florence ^a,b   Sennepin, Alexis ^a,b   Ermonval, Myriam ^c   Dorgham, Karim ^a,b   Debre, Patrice ^a,b   Vieillard, Vincent ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA 5 PROTEIN; LIGAND; NATURAL CYTOTOXICITY RECEPTOR NKP44; NATURAL KILLER CELL RECEPTOR; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ISOPROTEIN; MLL5 PROTEIN, HUMAN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NEUTRALIZING ANTIBODY;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOBIOLOGY; INNATE IMMUNITY; LYSIS; NATURAL KILLER CELL; TRANSFORMED CELL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE LIBRARY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; TWO HYBRID SYSTEM;

AMINO ACID MOTIFS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; GENE LIBRARY; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; ORGAN SPECIFICITY; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84888256546     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-489054     Document Type: Article

References (47)

1. Yokoyama WM. Natural killer cell immune responses. Immunol Res. 2005;32(1-3):317-325.
2. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
3. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142(6):847-856.
4. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheralblood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244): 1795-1799.
5. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5): 495-502.
6. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
7. Vacca P, Cantoni C, Prato C, et al. Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol. 2008;20(11):1395-1405.
8. Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci USA. 2010;107(24):10961-10966.
9. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood. 2005;106(6):2076-2082.
10. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in nonmajor histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187(12):2065-2072.
11. Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 1999;189(5):787-796.
12. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409(6823):1055-1060.
13. Arnon TI, Achdout H, Levi O, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005;6(5): 515-523.
14. Ho JW, Hershkovitz O, Peiris M, et al. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol. 2008;82(4):2028-2032.
15. Hecht ML, Rosental B, Horlacher T, et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res. 2009;8(2):712-720.
16. Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol. 2009; 83(16):8108-8121.
17. Pogge von Strandmann E, Simhadri VR, von Tresckow B, et al. Human leukocyte antigen-Bassociated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27(6):965-974.
18. Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495-1503.
19. Li Y, Wang Q, Mariuzza RA. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med. 2011;208(4):703-714.
20. Vieillard V, Strominger JL, Debŕe P. NK cytotoxicity against CD41 T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA. 2005;102(31):10981-10986.
21. Ward J, Bonaparte M, Sacks J, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110(4): 1207-1214.
22. Vieillard V, Le Grand R, Dausset J, Debŕe P. A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD41 T cell depletion in SHIVinfected macaques. Proc Natl Acad Sci USA. 2008;105(6):2100-2104.
23. Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993;75(4): 791-803.
24. Baychelier F, Nardeux PC, Cajean-Feroldi C, et al. Involvement of the Gab2 scaffolding adapter in type I interferon signalling. Cell Signal. 2007; 19(10):2080-2087.
25. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS ONE. 2007;2(12):e1339.
26. Emerling BM, Bonifas J, Kratz CP, et al. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 2002;21(31): 4849-4854.
27. Dunn C, Chalupny NJ, Sutherland CL, et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med. 2003;197(11):1427-1439.
28. Deng LW, Chiu I, Strominger JL. MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc Natl Acad Sci USA. 2004;101(3):757-762.
29. Zhou P, Wang Z, Yuan X, et al. Mixed lineage leukemia 5 (MLL5) protein regulates cell cycle progression and E2F1-responsive gene expression via association with host cell factor-1 (HCF-1). J Biol Chem. 2013;288(24): 17532-17543.
30. Liu J, Cheng F, Deng LW. MLL5 maintains genomic integrity by regulating the stability of the chromosomal passenger complex through a functional interaction with Borealin. J Cell Sci. 2012;125(Pt 19):4676-4685.
31. Sebastian S, Sreenivas P, Sambasivan R, et al. MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. Proc Natl Acad Sci USA. 2009;106(12):4719-4724.
32. Ali M, Rinćon-Arano H, Zhao W, et al. Molecular basis for chromatin binding and regulation of MLL5. Proc Natl Acad Sci USA. 2013;110(28): 11296-11301.
33. Liu H, Westergard TD, Hsieh JJ. MLL5 governs hematopoiesis: a step closer. Blood. 2009;113(7): 1395-1396.
34. Damm F, Oberacker T, Thol F, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol. 2011;29(6):682-689.
35. Yew CW, Lee P, Chan WK, et al. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers. Cancer Res. 2011;71(21):6696-6707.
36. Fujiki R, Chikanishi T, Hashiba W, et al. GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature. 2009;459(7245):455-459.
37. Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens. 2003;61(5):335-343.
38. Fausther-Bovendo H, Sol-Foulon N, Candotti D, et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD41 T cells. AIDS. 2009;23(9):1077-1087.
39. Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debŕe P. HIV gp41 engages gC1qR on CD41 T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog. 2010;6:e1000975.
40. Madrid AS, Ganem D. Kaposi's sarcomaassociated herpesvirus ORF54/dUTPase downregulates a ligand for the NK activating receptor NKp44. J Virol. 2012;86(16):8693-8704.
41. Reichsman F, Smith L, Cumberledge S. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J Cell Biol. 1996;135(3): 819-827.
42. Flaumenhaft R, Moscatelli D, Rifkin DB. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol. 1990;111(4):1651-1659.
43. Cantoni C, Ponassi M, Biassoni R, et al. The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure. 2003;11(6):725-734.
44. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235(1):267-285.
45. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190.
46. Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006;129(Pt 9): 2416-2425.
47. Schwinn N, Vokhminova D, Sucker A, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer. 2009;124(7): 1594-1604.